Evidence map›Paper›PMID 30953664›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2019

Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson's disease.

Maria Eleni Karakatsani, Shutao Wang, Gesthimani Samiotaki, Tara Kugelman, Oluyemi O Olumolade, Camilo Acosta, Tao Sun, Yang Han, Hermes A S Kamimura, Vernice Jackson-Lewis and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Drug delivery to the central nervous system.Nature reviews. Materials · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria Eleni KarakatsaniDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Shutao WangDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Gesthimani SamiotakiDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Tara KugelmanDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Oluyemi O OlumoladeDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Camilo AcostaDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Tao SunDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Yang HanDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Hermes A S KamimuraDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Vernice Jackson-LewisDepartments of Pathology & Cell Biology, Columbia University, New York, NY 10032, USA; Departments of Neurology, Columbia University, New York, NY 10032, USA; the Center for Motor Neuron Biology and Disease, Columbia University, New York, NY 10032, USA; the Columbia Translational Neuroscience Initiative, Columbia University, New York, NY 10032, USA.
Serge PrzedborskiDepartments of Pathology & Cell Biology, Columbia University, New York, NY 10032, USA; Departments of Neurology, Columbia University, New York, NY 10032, USA; the Center for Motor Neuron Biology and Disease, Columbia University, New York, NY 10032, USA; the Columbia Translational Neuroscience Initiative, Columbia University, New York, NY 10032, USA. Electronic address: sp30@columbia.edu.
Elisa KonofagouDepartments of Biomedical Engineering, Columbia University, New York, NY 10032, USA; Departments of Radiology, Columbia University, New York, NY 10032, USA. Electronic address: ek2191@columbia.edu.

Funding

Assessment of Ultrsound-facilitated Neurotherapeutics in Alzheimer's DiseaseR01AG038961 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI KONOFAGOU, ELISA E. · 2011 to 2020
$5.1M
Optimization of ultrasound-facilitated blood-brain barrier openingR01EB009041 · NIBIB · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI KONOFAGOU, ELISA E. · 2008 to 2017
$4.4M
Protein prenylation inhibition for the treatment of tauopathiesR01NS107442 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PRZEDBORSKI, SERGE E · 2018 to 2022
$3.1M
Role of MMP-9 in selective motor neuron degeneration in ALSR01NS072428 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PRZEDBORSKI, SERGE E · 2013 to 2017
$1.7M
Assessment of ultrasound-facilitated neurotherapeutics in Alzheimer's diseaseR56AG038961 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KONOFAGOU, ELISA E. · 2023 to 2024
$1.6M
Non-cell Autonomous Role of Synuclein in NeurodegenerationR21NS099862 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PRZEDBORSKI, SERGE E · 2017 to 2018
$440k
NIA NIH HHS R01 AG038961NIA NIH HHS R56 AG038961NIBIB NIH HHS R01 EB009041NINDS NIH HHS R01 NS072428NINDS NIH HHS R01 NS107442NINDS NIH HHS R21 NS099862
6 · The paper itself

Abstract

The blood-brain barrier (BBB) prevents most drugs from gaining access to the brain parenchyma, which is a recognized impediment to the treatment of neurodegenerative disorders like Parkinson's disease (PD). Focused ultrasound (FUS), in conjunction with systemically administered microbubbles, opens the BBB locally, reversibly and non-invasively. Herein, we show that neither FUS applied over both the striatum and the ventral midbrain, without neurotrophic factors, nor intravenous administration of neurotrophic factors (either through protein or gene delivery) without FUS, ameliorates the damage to the nigrostriatal dopaminergic pathway in the sub-acute MPTP mouse model of early-stage PD. Conversely, the combination of FUS and intravenous neurotrophic (protein or gene) delivery attenuates the damage to the nigrostriatal dopaminergic pathway, by allowing the entry of these agents into the brain parenchyma. Our findings provide evidence that the application of FUS at the early stages of PD facilitates critical neurotrophic delivery that can curb the rapid progression of neurodegeneration while improving the neuronal function, seemingly opening new therapeutic avenues for the early treatment of diseases of the central nervous system.

Indexed as

Genetic TherapyUltrasonic TherapyAnimalsBrainGenetic VectorsGlial Cell Line-Derived Neurotrophic FactorMaleMice, Inbred C57BLMicrobubblesNeurturinParkinsonian DisordersRecombinant ProteinsGlial Cell Line-Derived Neurotrophic FactorNeurturinNRTN protein, humanRecombinant ProteinsBlood-brain barrierFocused ultrasoundNeurodegenerationNeurorestorationNeurotrophic factor

Identifiers

PMID30953664
PMCPMC6618306

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.